What Is Tirzepatide?
Tirzepatide is a synthetic dual agonist that simultaneously activates two incretin hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism sets it apart from single-receptor GLP-1 agonists and has made it one of the most exciting compounds in current metabolic research.
Mechanism of Action
By targeting both GLP-1 and GIP receptors, Tirzepatide engages two complementary pathways involved in glucose homeostasis and energy balance. GLP-1 receptor activation suppresses appetite, slows gastric emptying, and stimulates insulin secretion. GIP receptor activation enhances insulin sensitivity in adipose tissue and may amplify the metabolic effects of GLP-1 signalling.
What Research Shows
Clinical trials have demonstrated that Tirzepatide produces greater reductions in body weight and HbA1c compared to GLP-1 receptor agonists alone. Research has also shown improvements in triglyceride levels, blood pressure, and markers of liver health.
Research Applications
- Obesity and body composition research
- Type 2 diabetes and glycaemic control studies
- Cardiovascular and cardiometabolic risk research
- Lipid metabolism and dyslipidaemia investigation
- Comparative incretin pharmacology
Freeze-Dried Format
Our Tirzepatide is available in lyophilised (freeze-dried) powder form, ensuring maximum stability and bioactivity for research applications.
Important Disclaimer
This compound is intended strictly for research purposes only. It is not approved for human consumption and is not intended to diagnose, treat, cure, or prevent any disease.
🛒 Shop This Compound
Tirzepatide is available as part of our Metabo GLP-3 Peptide collection at SONOCOUTURE.